Newly approved, freshly sourced.

First-in-class broad RAS(ON) inhibitor approved for metastatic pancreatic cancer

Rasonque is a new once-daily pill for advanced pancreatic cancer, one of the hardest cancers to treat. It works by jamming a protein called RAS that's stuck in the 'on' position in many pancreatic tumors — and unlike earlier RAS-targeting drugs, it isn't limited to just one specific RAS mutation, so it can help a wider range of patients.